These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34073847)

  • 1. Ceftolozane/Tazobactam for Resistant Drugs
    Giaccari LG; Pace MC; Passavanti MB; Gargano F; Aurilio C; Sansone P
    Life (Basel); 2021 May; 11(6):. PubMed ID: 34073847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications.
    Maraolo AE; Mazzitelli M; Trecarichi EM; Buonomo AR; Torti C; Gentile I
    Int J Antimicrob Agents; 2020 Mar; 55(3):105891. PubMed ID: 31923569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
    Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
    Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Ceftolozane-Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections.
    Holger DJ; Rebold NS; Alosaimy S; Morrisette T; Lagnf A; Belza AC; Coyne AJK; El Ghali A; Veve MP; Rybak MJ
    Infect Dis Ther; 2022 Oct; 11(5):1965-1980. PubMed ID: 36048335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experience.
    Buonomo AR; Maraolo AE; Scotto R; Foggia M; Zappulo E; Congera P; Parente S; Gentile I
    Infection; 2020 Apr; 48(2):303-307. PubMed ID: 31981091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Dimer, but Not Monomer, of Tobramycin Potentiates Ceftolozane against Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa and Delays Resistance Development.
    Idowu T; Zhanel GG; Schweizer F
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections.
    Jorgensen SCJ; Trinh TD; Zasowski EJ; Lagnf AM; Simon SP; Bhatia S; Melvin SM; Steed ME; Finch NA; Morrisette T; Estrada SJ; Rosenberg JR; Davis SL; Rybak MJ
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Resistance to Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Extensively Drug-Resistant (XDR) and Multidrug-Resistant (MDR)
    Meschiari M; Orlando G; Kaleci S; Bianco V; Sarti M; Venturelli C; Mussini C
    Antibiotics (Basel); 2021 Oct; 10(10):. PubMed ID: 34680805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic Literature Review of Real-world Evidence of Ceftolozane/Tazobactam for the Treatment of Respiratory Infections.
    Puzniak L; Dillon R; Palmer T; Collings H; Enstone A
    Infect Dis Ther; 2021 Sep; 10(3):1227-1252. PubMed ID: 34278551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.
    Vickery SB; McClain D; Wargo KA
    Pharmacotherapy; 2016 Oct; 36(10):e154-e159. PubMed ID: 27522066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial.
    Pérez A; Gato E; Pérez-Llarena J; Fernández-Cuenca F; Gude MJ; Oviaño M; Pachón ME; Garnacho J; González V; Pascual Á; Cisneros JM; Bou G
    J Antimicrob Chemother; 2019 May; 74(5):1244-1252. PubMed ID: 30753505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa.
    Xipell M; Paredes S; Fresco L; Bodro M; Marco F; Martínez JA; Soriano A
    J Glob Antimicrob Resist; 2018 Jun; 13():165-170. PubMed ID: 29366723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
    Henderson A; Tan E; McCarthy KL; Paterson DL
    Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftolozane-tazobactam for the treatment of multidrug-resistant
    Alessa MA; Almangour TA; Alhossan A; Alkholief MA; Alhokail M; Tabb DE
    Am J Health Syst Pharm; 2018 May; 75(9):e184-e188. PubMed ID: 29691260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftolozane and tazobactam for the treatment of hospital acquired pneumonia.
    Martin-Loeches I; Bisanti A; Diaz E; Rodriguez A
    Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1177-1185. PubMed ID: 32662691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
    Farrell DJ; Sader HS; Flamm RK; Jones RN
    Int J Antimicrob Agents; 2014 Jun; 43(6):533-9. PubMed ID: 24856078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activity of ceftolozane/tazobactam tested against contemporary (2015-2017) Pseudomonas aeruginosa isolates from a global surveillance programme.
    Shortridge D; Pfaller MA; Streit JM; Flamm RK
    J Glob Antimicrob Resist; 2020 Jun; 21():60-64. PubMed ID: 31648032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an
    Montero M; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Angulo-Brunet A; Padilla E; Prim N; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32041712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance.
    Werarak P; Kiratisin P; Thamlikitkul V
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S126-38. PubMed ID: 20364567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital.
    López-Calleja AI; Morilla Morales E; Nuñez Medina R; Fernández Esgueva M; Sahagún Pareja J; García-Lechuz Moya JM; Ferrer Cerón I; Viñuelas Bayon J; Rezusta López A
    Rev Esp Quimioter; 2019 Feb; 32(1):68-72. PubMed ID: 30547503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.